A Study to Evaluate the Pharmacokinetics and Safety of Golcadomide in Participants With Severe Renal Impairment and End-Stage Renal Disease Compared With Participants With Normal Renal Function
A Phase 1, Multi-center, Single-dose, Open-label Study to Evaluate the Pharmacokinetics and Safety of Golcadomide (BMS-986369) in Participants With Severe Renal Impairment and End-Stage Renal Disease Compared With Participants With Normal Renal Function
The purpose of this study is to assess the pharmacokinetics and safety of golcadomide (BMS-986369) in matched healthy participants with normal renal function, adult participants with severe renal impairment, and participants with end-stage renal disease.
研究概览
地位
地位
干预/治疗
干预/治疗
研究类型
研究类型
注册 (估计的)
注册
阶段
阶段
- 阶段1
联系人和位置
学习联系方式
学习联系方式
- 姓名:First line of the email MUST contain NCT # and Site #.
研究联系人备份
- 姓名:BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
- 电话号码:855-907-3286
- 邮箱:Clinical.Trials@bms.com
学习地点
-
-
Arizona
-
Chandler、Arizona、美国、85225
- 招聘中
- Arizona Clinical Trials - Chandler
-
接触:
- Anita Kohli, Site 0003
- 电话号码:434-825-0921
-
-
Florida
-
Miami Lakes、Florida、美国、33014
- 招聘中
- Panax Clinical Research
-
接触:
- Robert Perry, Site 0002
- 电话号码:305-698-4500
-
Orlando、Florida、美国、32809-3017
- 招聘中
- Orlando Clinical Research Center OCRC
-
接触:
- Thomas Marbury, Site 0001
- 电话号码:407-257-3462
-
-
参与标准
资格标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Participant must have severe renal impairment (RI).
- Participant must have end-stage renal disease (ESRD).
- Participant must be healthy male and female participants not of childbearing potential between 18 and 84 years of age (inclusive) with a BMI between 18 and 40 kg/m2, (inclusive) at screening.
Exclusion Criteria:
- Any surgical or medical condition possibly affecting drug absorption, distribution, metabolism, and excretion (ADME).
- Any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the participant from participating in the study
- Known or suspected active autoimmune disorder, or any history of known or suspected congenital or acquired immunodeficiency state or condition that would compromise the participant's immune status
- Other protocol-defined inclusion/exclusion criteria apply.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:非随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
手臂数量
武器和干预
参与者组/臂参与者组/臂 |
干预/治疗干预/治疗 |
|---|---|
|
实验性的:A组
|
Specified dose on specified days
其他名称:
|
|
实验性的:B组
|
Specified dose on specified days
其他名称:
|
|
实验性的:C组
|
Specified dose on specified days
其他名称:
|
研究衡量的是什么?
主要结果指标
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
Maximum observed concentration (Cmax)
大体时间:Up to Day 44
|
Up to Day 44
|
|
Time of maximum observed plasma concentration (Tmax)
大体时间:Up to Day 44
|
Up to Day 44
|
|
Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T))
大体时间:Up to Day 44
|
Up to Day 44
|
|
Area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUC(INF))
大体时间:Up to Day 44
|
Up to Day 44
|
次要结果测量
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
Number of participants with adverse events (AEs)
大体时间:Up to Day 60
|
Up to Day 60
|
|
Number of participants with serious adverse events (SAEs)
大体时间:Up to Day 60
|
Up to Day 60
|
|
Number of participants with physical examination (PE) abnormalities
大体时间:Up to Day 44
|
Up to Day 44
|
|
Number of participants with vital sign abnormalities
大体时间:Up to Day 44
|
Up to Day 44
|
|
Number of participants with electrocardiogram (ECG) abnormalities
大体时间:Up to Day 44
|
Up to Day 44
|
|
Number of participants with clinical safety laboratory abnormalities
大体时间:Up to Day 44
|
Up to Day 44
|
|
Dialysate clearance of golcadomide from plasma (CLD)
大体时间:Day 1
|
Day 1
|
合作者和调查者
调查人员
调查人员
- 研究主任:Bristol-Myers Squibb、Bristol-Myers Squibb
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
学习开始
初级完成 (估计的)
初级完成
研究完成 (估计的)
研究完成
研究注册日期
首次提交
首次提交
首先提交符合 QC 标准的
首先提交符合 QC 标准的
首次发布 (实际的)
首次发布
研究记录更新
最后更新发布 (实际的)
最后更新发布
上次提交的符合 QC 标准的更新
上次提交的符合 QC 标准的更新
最后验证
最后验证
更多信息
与本研究相关的术语
关键字
其他相关的 MeSH 术语
其他研究编号
其他研究编号
- CA073-1033
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html
IPD 共享时间框架
See Plan Description
IPD 共享访问标准
See Plan Description
IPD 共享支持信息类型
- 研究方案
- 树液
- 企业社会责任
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.